Finance News – Prescriptions
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Shares
Tariffs
Stock
Investors
Ceo
Stock Market
Crypto Assets
Ethereum
Cryptocurrency
Price
Markets
Xrp
Eth
Etf
Bse
Earnings
Ipo
Stablecoin
Investment
Blockchain
Revenue
Solana
Index
Trade
Sec
Inflation
Interest Rates
Wall Street
Token
Sensex
Coinbase
Treasury
Federal Reserve
Nasdaq
Traders
Profit
Nse
China
Nifty
Bse Sensex
Sp 500
Investor
Gold
Tesla
Company
Economy
Osl
High Yield Savings
Household Budgets
Stord
Cronos Trust
Acheron Trading
South Korean Markets
Whale Investors
Laurus Lab
Pension Assets
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Quartz • May 30, 2025
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →
The Guardian – Business • May 07, 2025
Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
Novo Nordisk's reduced earnings outlook reflects challenges in maintaining sales momentum for its obesity treatment, as competitive pressures from US rivals increasingly impact its...
Read Full Article →